Funding for this research was provided by:
Received: 4 April 2022
Accepted: 22 September 2022
First Online: 1 October 2022
Change Date: 3 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12931-023-02351-3
: Participants provided written consent to participate in NHANES using a protocol approved by the National Center for Health Statistics Research Ethics Review Board. All the data used in the present analysis are de-identified and publicly available, and did not need additional ethical approval by the Swedish Ethical Review Authority in accordance with national research regulations.
: ME discloses personal fees from Astra Zeneca outside this study. DM Is a former employee and current shareholder of GlaxoSmithKline and a consultant to AstraZeneca and the COPD Foundation, and is also an expert witness for the Schlesinger Law Firm.
: Not applicable.
: The funding sources had no influence of the planning, conduct or reporting of the study.